Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
329.9 USD | -0.08% | +0.34% | +73.17% |
04-11 | Health Care Slips on Risk Bias -- Health Care Roundup | DJ |
04-09 | CL King Downgrades ShockWave Medical to Neutral From Buy, Cuts Price Target to $335 From $368 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 68.32 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+73.17% | 12.38B | B- | ||
-20.51% | 7.61B | C+ | ||
+14.29% | 7.11B | C- | ||
+4.77% | 5.83B | B | ||
+11.77% | 5.35B | D+ | ||
+29.65% | 4.63B | - | ||
-19.09% | 4.02B | B- | ||
-30.95% | 2.16B | C | ||
+1.24% | 2.01B | - | ||
+4.85% | 1.88B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SWAV Stock
- Ratings Shockwave Medical, Inc.